News|Videos|January 27, 2023
Comparing BTK Inhibitors in the Treatment of Relapsed CLL
Drs Susan O’Brien and Catherine Coombs describe the design and outcomes of the ELEVATE-RR and ALPINE trials that compare BTK inhibitors in CLL.
Advertisement
Episodes in this series
Advertisement
Related to this article
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
A flood-damaged Pfizer joint-venture plant in India that makes injectable chemotherapy may not resume supply until mid-to-late 2028.
Preoperative botensilimab plus balstilimab produced a pathologic major response in 36% of patients with pMMR and 100% of those with dMMR resectable colon cancer.
Sunnie Kim, MD, explains how she uses baseline and postsurgical ctDNA to guide de-escalation conversations for patients struggling after surgery.
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative PD-L1 gastroesophageal cancer.
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.
Advertisement
Advertisement
Trending on CancerNetwork
1
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
2
Closing the Gaps in Precision Oncology for Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5